Exploration of the treatment of liver fibrosis in Wilson disease based on the Traditional Chinese Medicine theory of "micro-lumps in liver"

Wenjie HAO; Wenming YANG; Taohua WEI; Wei DONG; Xiang LI; Hailing JIANG; Yue YANG; Nannan QIAN

doi:10.3969/j.issn.1006-2157.2022.03.016

您当前的位置：

首页 >

文章列表页 >

Exploration of the treatment of liver fibrosis in Wilson disease based on the Traditional Chinese Medicine theory of "micro-lumps in liver"

Clinical Studies | 更新时间：2022-04-01

- Exploration of the treatment of liver fibrosis in Wilson disease based on the Traditional Chinese Medicine theory of "micro-lumps in liver"
- Journal of Beijing University of Traditional Chinese Medicine Vol. 45, Issue 3, Pages: 307-312(2022)
- 作者机构：
  
  1.安徽中医药大学　合肥　 230038
  2.新安医学教育部重点实验室
  3.安徽中医药大学第一附属医院
- 作者简介：
  
  Prof. YANG Wenming, Ph. D. , Chief physician, Doctoral Supervisor, The First Affiliated Hospital of Anhui University of Chinese Medicine, No.117 Meishan Road, Shushan District, Hefei 230031, China. E-mail: yangwm8810@126.com
- 基金信息：
  
  National Natural Science Foundation of China(81973825);National Administration of Traditional Chinese Medicine(2019XZZX-NB001);University Synergy Innovation Program of Anhui Province(GXXT-2020-025)
- DOI：10.3969/j.issn.1006-2157.2022.03.016
  CLC： R256.4
- Received：08 October 2021，
  
  Published：30 March 2022
- 稿件说明：
移动端阅览
Wenjie HAO, Wenming YANG, Taohua WEI, et al. Exploration of the treatment of liver fibrosis in Wilson disease based on the Traditional Chinese Medicine theory of "micro-lumps in liver"[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(3): 307-312.
DOI：

Wenjie HAO, Wenming YANG, Taohua WEI, et al. Exploration of the treatment of liver fibrosis in Wilson disease based on the Traditional Chinese Medicine theory of "micro-lumps in liver"[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(3): 307-312. DOI： 10.3969/j.issn.1006-2157.2022.03.016.

摘要

肝络微癥积是各种慢性肝病发展致终末期必经的一个病理阶段，相当于西医学中肝纤维化等疾病。中医认为肝络微癥积的基本病机为本虚标实，正气亏虚为本，痰浊、瘀血为标，其中痰瘀互结是其关键的病理因素，并贯穿本病始终。消补兼施、痰瘀同治乃本病治疗的基本原则。研究表明，肝豆状核变性导致的肝纤维化属于肝络微癥积的范畴，本文基于肝络微癥积学说，探讨了肝豆状核变性肝纤维化的中医病因病机、临床转归及其中医药干预策略。认为肝豆状核变性肝纤维化是发生在肝络的微癥积，痰瘀互结是本病基本病理特征，正气亏虚是其发病的关键，治疗总则不外乎消补兼施、痰瘀同治。旨为今后肝豆状核变性肝纤维化的临床防治提供借鉴。

Abstract

Micro-lumps in liver is a pathological stage that occurs in the late stage of the development of a variety of chronic liver diseases ; itis equivalent to liver fibrosis and other diseases in western medicine.According to traditional Chinese medicine (TCM)

the basic pathogenesis of micro-lumps in liver is deficiency of the original qi

deficiency of the vital qi

and turbidities of phlegm and blood stasis

the foundation is Qi deficiency

and the presentation is phlegm turbidity and blood stasis

which forming the basic pathogenesis of micro-lumps in liver. Besides

the phlegm turbidity and blood stasisamong which the intermingled phlegm and blood stasis isare the key pathological factorsaffecting the whole disease throughout the whole process of the disease.The basic principle of the treatment of this disease is to simultaneously treat phlegm and blood stasis.Studies have shown that liver fibrosis in Wilson disease belongs to the category of micro-lumps in liver.Based on the theory of micro-lumps in liver

this paper discusses the TCM etiology

pathogenesis

clinical outcomes

and intervention strategies of liver fibrosis in Wilson disease.It is concluded that the disease is the accumulation of micro-lumps in liver

the intermingled phlegm and blood stasis is the basic pathological feature of the disease

the deficiency of vital qi is the key to its pathogenesis

and the general treatment is aimed at strengthening body resistance to eliminate pathogenic factors and dispel phlegm and remove blood stasis at the same time.We providea reference for the clinical prevention and treatment of liver fibrosis in Wilson disease.

关键词

Keywords

references

杨文明．中西医结合神经病学临床研究 [M]. 北京：人民卫生出版社， 2019 : 236 － 237 .

GEROSA C , FANNI D , CONGIU T , et al . Liver pathology in Wilson’s disease: From copper overload to cirrhosis [J]. J InorgBiochem , 2019 ， 193 ( 2 )： 106 － 111 .

BANDMANN O , WEISS KH , KALER SG . Wilson’s disease and other neurological copper disorders [J]. Lancet Neurol , 2015 ， 14 ( 1 )： 103 － 113 .

祝强，杨继敏，刘中亮．八种评分系统对肝硬化失代偿期患者短期预后的预测价值 [J]. 中国医药科学， 2021 ， 11 ( 19 )： 18 － 22 .

郑帅，张凯，高雨秋，等．苦参总黄酮调控Nrf2/HO-1通路对肝纤维化大鼠的机制研究 [J]. 中国病理生理杂志， 2021 ， 37 ( 12 )： 2197 － 2204 .

张巍，邵明亮，张海丛，等．扶正化瘀片调节肝纤维化miR-122基因相关因子表达研究 [J]. 北京中医药大学学报， 2018 ， 41 ( 1 )： 76 － 82 .

韩仕庆，曹文富，何娟，等．丹参含药血清对HSCs中Smo和α-SMA表达的影响 [J]. 中药药理与临床， 2015 ， 31 ( 5 )： 79 － 82 .

徐列明，刘平，沈锡中，等．肝纤维化中西医结合诊疗指南(2019年版) [J]. 中国中西医结合杂志， 2019 ， 39 ( 11 )： 1286 － 1295 .

骆欢欢，王新华．从肝瘀正虚论肝纤维化治疗思路 [J]. 中医杂志， 2010 ， 51 ( 5 )： 463 － 465 .

张荣信，杨文明，汪美霞．肝豆状核变性患者肝纤维化的发病机制及中医治疗 [J]. 中医药临床杂志， 2012 ， 24 ( 3 )： 262 － 264 .

杨文明，张春海，李瑞娟，等．毒邪在肝豆状核变性致病中的作用 [J]. 中国实验方剂学杂志， 2009 ， 15 ( 11 )： 108 － 111 .

张永生，徐珊，朱飞叶，等．肝纤维化“微癥积”中医病证探究 [J]. 中华中医药杂志， 2014 ， 29 ( 9 )： 2903 － 2905 .

唐露露，杨文明，谢文婷，等．肝豆扶木汤对Wilson病肝纤维化TX小鼠肝组织TβRⅠ、TβRⅡ和Smad4表达的影响 [J]. 中华中医药杂志， 2019 ， 34 ( 9 )： 4043 － 4047 .

魏涛华，杨文明，唐露露，等．基于网络药理学探讨肝豆扶木汤治疗肝豆状核变性肝纤维化的作用机制及实验验证 [J]. 中国中西医结合杂志， 2021 ， 41 ( 8 )： 981 － 990 .

肖政华，邹艳，杨辉，等．扶肝化纤汤含药血清对TGF-β1诱导HSC-T6细胞增殖及TGF-β1/Smad信号通路的影响 [J]. 中医杂志， 2019 ， 60 ( 19 ): 1673 － 1678 .

汪美霞，汪长春．杨文明从痰瘀论治肝豆状核变性 [J]. 中医药临床杂志， 2017 , 29 ( 7 )： 983 － 985 .

张秋云，刘绍能，李媛娥．从痰论治肝纤维化探讨 [J]. 中国中医药信息杂志， 2007 , 14 ( 11 )： 86 － 87 .

周涛，鲍远程，谢道俊，等．从通腑化瘀论治肝豆状核变性及其肝纤维化 [J]. 中医药临床杂志， 2013 ， 25 ( 11 )： 968 － 970 .

王振常，黄晶晶，夏兰，等．从痰毒瘀损肝体探讨肝炎后肝纤维化发病机制渊薮 [J]. 辽宁中医药大学学报， 2010 ， 12 ( 12 )： 48 － 50 .

彭勃，闫永彬．从彭勃治“暗瘀”说探索肝纤维化的中医论治 [J]. 中华中医药杂志， 2007 , 22 ( 11 ) ： 782 － 784 .

陈卓群，刘凤斌．从邓铁涛软肝煎谈肝硬化中医药治疗 [J]. 中国中医药信息杂志， 2018 ， 25 ( 3 )： 119 － 120 .

杨文明，洪亮，汪美霞，等．肝豆扶木汤对实验性Wilson病模型大鼠肝铜、血清铜及肝组织自由基代谢的影响 [J]. 中医药临床杂志， 2010 ， 22 ( 11 )： 1010 － 1012 .

段桂姣，王振常．中医治疗肝纤维化组方规律 [J]. 中医学报， 2020 ， 35 ( 4 ): 894 － 900 .

齐书妍，黄华，李永坤，等．莪术醇对非酒精性脂肪性肝大鼠肝功能和肝纤维化的影响及机制 [J]. 中国应用生理学杂志， 2021 ， 37 ( 6 )： 611 － 615 .

徐新杰，刘旭东，赵壮志，等．大黄䗪虫丸对大鼠原代肝星状细胞BAMBI表达的影响 [J]. 北京中医药大学学报， 2018 ， 41 ( 7 )： 572 － 578 .

GONG Z ， LIN J ， ZHENG J ， et al . Dahuangzhechong pill attenuates CCl4-induced rat liver fibrosis viathe PI3K-Akt signaling pathway [J]. J Cell Biochem ， 2020 ， 121 ( 2 )： 1431 － 1440 .

李晖，杨琪，韩朋丽，等．益气逐瘀解毒颗粒调控MMPs/TIMPs平衡抗大鼠肝纤维化作用研究 [J]. 新中医， 2019 ， 51 ( 5 )： 17 － 22 .

WEI TH , HAO WJ , TANG LL , et al . Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model. Front Pharmacol . 2021 ， 15 ( 12 )： 622268 .

杨文明，洪亮，董婷，等．肝豆扶木汤对实验性Wilson病模型大鼠肝损害的保护作用 [J]. 中医药临床杂志， 2010 ， 22 ( 11 )： 1013 － 1016 .

杨文明，唐露露，谢文婷，等．肝豆扶木汤对TX小鼠肝纤维化TGF-β-1/Smad信号通路的影响 [J]. 中西医结合心脑血管病杂志， 2018 ， 16 ( 4 )： 404 － 407 .

唐露露，刘丹青，李睿，等．肝豆扶木汤对TX小鼠肝纤维化的保护作用及机制研究 [J]. 中国中西医结合杂志， 2018 ， 38 ( 12 )： 1461 － 1466 .

唐露露，张静，魏涛华，等．肝豆扶木汤对CuCl 2 诱导的HepG2细胞氧化损伤的保护作用和机制 [J]. 中国实验方剂学杂志， 2021 ， 27 ( 12 )： 48 － 56 .

杨文明，方芳，汪美霞，等．肝豆扶木汤治疗Wilson病肝纤维化的临床研究 [J]. 中医药临床杂志， 2014 ， 26 ( 11 )： 1111 － 1113 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The role of the LncRNA Meg3-regulated PI3K/Akt/mTOR pathway in Gandouling-mediated amelioration of hepatic fibrosis in Wilson disease via hepatic stellate cell autophagy

Multi-omics investigation into the biological implications in rats with liver fibrosis with syndrome of liver yin deficiency

Effects of Gandou Fumu Decoction on hepatic fibrosis, iron metabolism, and ferroptosis in patients with hepatolenticular degeneration

Expression of miR-122-related factors of liver fibrosis regulated by Fuzheng Huayu Tablet

Study of liver fibrosis rat model with pattern of liver-qi stagnation and validation of pattern time window by TCM formulas treatment

Related Author

WANG Han

YANG Wenming

JI Meiyan

SUN Lanting

HUA Daiping

XUAN Qiaoyu

WANG Zhen

LIU Shuangqiao

Related Institution

Key Laboratory of Xin′an Medicine, Ministry of Education

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine

Clinical College of Integrated Traditional Chinese and Western Medicine, North Sichuan Medical College, Nanchong

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences

Research Center,Fifth Hospital of Shijiazhuang City

AI问答

Postal code：100029
Tel：(010)53911857 Email：jbutcm@bucm.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰